Form 4: Alkermes CFO Iain Michael Brown Reports Stock Transactions

Iain Michael Brown, CFO of Alkermes plc, reports the vesting and subsequent disposal of restricted stock units, resulting in changes to his beneficial ownership of ordinary shares.

Summary

• On February 22, 2025, Iain Michael Brown, the SVP and Chief Financial Officer of Alkermes plc, reported transactions involving ordinary shares.
• Specifically, 7,109 restricted stock units vested and were converted into ordinary shares.
• Following the vesting, 3,154 shares were disposed of at a price of $35.32.
• On February 23, 2025, 5,825 restricted stock units vested and were converted into ordinary shares.
• Following the vesting, 2,587 shares were disposed of at a price of $35.32.
• After these transactions, Brown directly owns 145,073 ordinary shares.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing, reflecting standard executive compensation practices. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in compliance with SEC regulations.
• The transactions reported are typical for executives who receive stock-based compensation as part of their overall remuneration.
• Similar filings are made by executives at comparable pharmaceutical companies like Biogen, Vertex Pharmaceuticals, and Gilead Sciences.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates